

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

6

1

28

6

Complete if Known		
Application Number	08/823,999	
Filing Date	March 25, 1997	
First Named Inventor	Campbell Rogers, et al.	
Group Art Unit	1644	Not Yet Assigned
Examiner Name	GAMBEL	Not Yet Assigned
Attorney Docket Number	MIT 7501	

Sheet 1 of 6 Attorney Docket Number MIT 7501

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner's
Signature

PHILIP GAMBEL

Date
Considered

11/10/98

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

86/10/90
U.S. PTO
50585

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2 of 6

Complete if Known

Application Number	08/823,999
Filing Date	March 25, 1997
First Named Inventor	Campbell Rogers, et al.
Group Art Unit	Not Yet Assigned 1644
Examiner Name	Not Yet Assigned GAMBEL

Attorney Docket Number

MIT 7501

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
R		AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," <i>Proc. Natl. Acad. Sci. USA</i> 85(19):7079-7083 (1988).	
		ALTIERI, et al., "Oligospecificity of the Cellular Adhesion Receptor MAC-1 Encompasses an Inducible Recognition Specificity for Fibrinogen," <i>J. Cell Biol.</i> 107(5):1893-1900 (1988).	
		ALTIERI, et al., "The Structural Motif Glycine 190-Valine 202 of the Fibrinogen Y Chain Interacts with CD11b/CD18 Integrin ($\alpha_M\beta_2$, Mac-1) and Promotes Leukocyte Adhesion," <i>J. Biol. Chem.</i> 268(3):1847-1853 (1993).	
		ANDERSON, et al., "Contributions of the Mac-1 Glycoprotein Family and Adherence-Dependent Granulocyte Functions: Structure-Function Assessments Employing Subunit-Specific Monoclonal Antibodies," <i>J. Immunol.</i> 137(1):15-27 (1986).	
		ASKEW, et al., "Molecular Recognition with Convergent Functional Groups. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components," <i>J. Am. Chem. Soc.</i> 111(3):1082-1080 (1989).	
		AULT, et al., "Cross-Reaction of a Rat-Anti-Mouse Phagocyte-Specific Monoclonal Antibody (ANTI-Mac-1) with Human Monocytes and Natural Killer Cells," <i>J. Immunol.</i> 126(1):359-364 (1981).	
		BLUME, et al., "Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," <i>Nucl. Acids Res.</i> 20(7):1777-1784 (1992).	
		CLACKSON, et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , 352(6336):624-688 (1991).	
		COONEY, et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human <i>c-myc</i> Gene <i>in Vitro</i> ," <i>Science</i> 241:456-459 (1988).	
		CROOKE, "Progress toward oligonucleotide therapeutics: pharmacodynamic properties," <i>FASEB J.</i> 7(6):533-539 (1993).	
R		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476 (1991).	

Examiner's Signature	PHILIP GAMBEL	Date Considered
----------------------	---------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

8/10/90

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

3

of

6

Complete if Known

Application Number	08/823,999
Filing Date	March 25, 1997
First Named Inventor	Campbell Rogers, et al.
Group Art Unit	Not Yet Assigned 1644
Examiner Name	Not Yet Assigned GAMBEL
Attorney Docket Number	MIT 7501

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
<i>Re</i>		DIAMOND, et al., "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1 (CD11b/CD18) for Four Distinct Adhesion Ligands," <i>J. Cell Bio.</i> 120(4):1031-1043 (1993).	
		DUVAL-VALENTIN, et al., "Specific inhibition of transcription of triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89(2):504-508 (1992).	
		ELLINGTON, et al., "In vitro selection of RNA molecules that bind specific ligands," <i>Nature</i> 346(6287):818-822 (1990).	
		ELLINGTON, et al., "Selected in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures," <i>Nature</i> 355(6363):850-852 (1992).	
		FISCHMAN, et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," <i>N. E. J. Med.</i> 331(8):496-501 (1994).	
		GRIGORIEV, et al., "A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via Inhibition of NF KB Binding to Interleukin-2 Receptor α -Regulatory Sequence," <i>J. Biol. Chem.</i> 267(5):3389-3395 (1992).	
		HOLT, et al., "An Oligomer Complementary to <i>c-myc</i> mRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation," <i>Mol. Cell. Biol.</i> 8(2):963-973 (1988).	
		INOUE, et al., "Expression of Polymorphonuclear Leukocyte Adhesion Molecules and Its Clinical Significance in Patients Treated With Percutaneous Transluminal Coronary Angioplasty," <i>JACC</i> 28(5):1127-1133 (1996).	
		ITAKURA, et al., "Synthesis and Use of Synthetic Oligonucleotides," <i>Ann. Rev. Biochem.</i> 53:323-356 (1984).	
		KABAT, et al., <u>Sequences of Proteins of Immunological Interest</u> , 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD 1987) (Title page and Table of Contents only).	
<i>Re</i>		LEWIS, et al., "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation," <i>Proc. R. Soc. Lond.</i> 236:123-140 and 141-162 (1989).	

Examiner's Signature	<i>Philip GAMBEL</i>	Date Considered	
----------------------	----------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

06/10/90

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	6	Attorney Docket Number	MIT 7501
-------	---	----	---	------------------------	----------

OTHER ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published			T ²
R		MAHER, et al., "Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation," <i>Science</i> 245:725-730 (1989)			
		McKINLAY, et al., "Rational Design of Antiviral Agents," <i>Ann. Rev. Pharmacol. Toxicol.</i> 29: 111-122 (1989).			
		MERRIFIELD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-2154 (1963).			
		MICKELSON, et al., "Leukocyte Activation With Platelet Adhesion After Coronary Angioplasty: A Mechanism for Recurrent Disease?" <i>JACC</i> 28(2):345-353 (1996).			
		MULLIGAN, "The Basic Science of Gene Therapy," <i>Science</i> 260:926-932 (1993).			
		NARANG, et al., "Chemical Synthesis of Deoxyligonucleotides by the Modified Triester Method," <i>Methods Enzymol.</i> , Vol. 65, Chapter 61, pp. 610-620 (The Academic Press, New York 1980).			
		OFFENSPERGER, et. al., "In Vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," <i>EMBO J.</i> 12(3):1257-1262 (1993).			
		ORSON, et al., "Oligonucleotide inhibition of IL2Ra mRNA transcription by promoter region collinear triplex formation in lymphocytes," <i>Nucl. Acids Res.</i> 19(12):3435-3441 (1991).			
		PEPIN, et al., "A Controlled Trial of Coricosteroids to Prevent Restenosis After Coronary Angioplasty," <i>Circulation</i> 81(6):1753-1761 (1990).			
		PERRY, et al., "The Use of 3D Modelling Databases for Identifying Structure Activity Relationships," in <u>QSAR: Quantitative Structure-Activity Relationships in Drug Design</u> , (Fauchère, ed.) pp. 189-193 (Alan R. Liss, Inc. 1989).			
R		PIETERSMA, et al., "Late Lumen Loss After Coronary Angioplasty Is Associated With the Activation Status of Circulating Phagocytes Before Treatment," <i>Circulation</i> 91(5):1320-1325 (1995).			

Examiner's Signature	Philip G. Gamble	10/10/98	Date Considered	10/10/98
----------------------	------------------	----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

6

Attorney Docket Number

Complete if Known

Application Number	08/823,999
Filing Date	March 25, 1997
First Named Inventor	Campbell Rogers, et al.
Group Art Unit	Not Yet Assigned 1644
Examiner Name	Not Yet Assigned G. M. B. G. L.

MIT 7501

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
<i>MR</i>		POSTEL, et al., "Evidence that a triplex-forming oligodeoxyribonucleotide binds to the <i>c-myc</i> promoter in HeLa cells, thereby reducing <i>c-myc</i> mRNA levels," <i>Proc. Natl. Acad. Sci. USA</i> 88(18):8227-8231 (1991).	
		RIPKA, "Computers picture the perfect drug," <i>New Scientist</i> 1617:54-57 (1988).	
		ROGERS, et al., "Inhibition of Experimental Neointimal Hyperplasia and Thrombosis Depends on the Type of Vascular Injury and the Site of Drug Administration," <i>Circulation</i> 88(3):1215-1221 (1993).	
		ROGERS, et al., "Monocyte Recruitment and Neointimal Hyperplasia in Rabbits Coupled Inhibitory Effects of Heparin," <i>Art. Thromb. Vasc. Bio.</i> 16:1312-1318 (1996).	
		ROGERS, et al., "Endovascular Stent Design Dictates Experimental Restenosis and Thrombosis," <i>Circulation</i> 91(12):2995-3001 (1995).	
		ROUVINEN, et al., "Computer and Drug Design," <i>Acta Pharmaceutica Fennica</i> 97:159-166 (1988).	
		SARIN, et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85(20):7448-7794 (1989).	
		SERRUYS, et al., "A Comparison of Ballon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease," <i>N. E. J. Med.</i> 331(8):489-495 (1994).	
		SHAW, et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," <i>Nucleic Acids Res.</i> 19(4):747-750 (1991).	
		SZOSTAK, "In Vitro Genetics," <i>TIBS</i> 17:89-93 (1992).	
<i>MR</i>		WICKSTROM, et al., "Human promyelocytic leukemia HL-60 cell proliferation and <i>c-myc</i> protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against <i>c-myc</i> mRNA," <i>Proc. Natl. Acad. Sci. USA</i> 85(4):1028-1032 (1988).	

Examiner's Signature	<i>Phillip G. M. B. G. L.</i>	Date Considered	11/10/98
----------------------	-------------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

6

Complete if Known

Application Number	08/823,999
Filing Date	March 25, 1997
First Named Inventor	Campbell Rogers, et al.
Group Art Unit	Not Yet Assigned 1644
Examiner Name	Not Yet Assigned G. M. B. L.

Attorney Docket Number

MIT 7501

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
M		YOUNG, et al., "Triple helix formation inhibits transcription elongation <i>in vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 88(22):10023-10026 (1991).	
1		ZAMECNIK, et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 75(1):280-284 (1978).	
1		ZAMECNIK, et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA," <i>Proc. Natl. Acad. Sci.</i> , 83(12):4143-4146 (1986).	
M		ZHU, et al., "Systemic Gene Expression After Intravenous DNA Delivery Into Adult Mice," <i>Science</i> 261:209-211 (1993).	

Examiner's Signature	PHILLIP G. M. B. L.	Date Considered	11/10/98
----------------------	---------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.31). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.